新型氟喹诺酮类药物ABT-492对革兰氏阳性和革兰氏阴性菌的体外抗菌及杀菌活性
In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
作者信息
Almer Laurel S, Hoffrage Jennifer B, Keller Erika L, Flamm Robert K, Shortridge Virginia D
机构信息
Infectious Diseases Research, R47T, AP52N, Abbott Laboratories, Abbott Park, IL 60064-3537, USA.
出版信息
Antimicrob Agents Chemother. 2004 Jul;48(7):2771-7. doi: 10.1128/AAC.48.7.2771-2777.2004.
Abstract
In vitro activities of ABT-492, ciprofloxacin, levofloxacin, trovafloxacin, moxifloxacin, gatifloxacin, and gemifloxacin were compared. ABT-492 was more potent against quinolone-susceptible and -resistant gram-positive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms. Bactericidal activity of ABT-492 was also evaluated.
摘要
比较了ABT-492、环丙沙星、左氧氟沙星、曲伐沙星、莫西沙星、加替沙星和吉米沙星的体外活性。ABT-492对喹诺酮敏感和耐药的革兰氏阳性菌更具活性，对肠杆菌科某些成员的活性与环丙沙星相似，对喹诺酮敏感的非发酵革兰氏阴性菌具有相当的活性。还评估了ABT-492的杀菌活性。
相似文献
1
In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.新型氟喹诺酮类药物ABT-492对革兰氏阳性和革兰氏阴性菌的体外抗菌及杀菌活性
Antimicrob Agents Chemother. 2004 Jul;48(7):2771-7. doi: 10.1128/AAC.48.7.2771-2777.2004.
2
In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.三种非氟喹诺酮类药物对代表性细菌分离株的体外活性。
Antimicrob Agents Chemother. 2001 Jun;45(6):1923-7. doi: 10.1128/AAC.45.6.1923-1927.2001.
3
In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci.新型胃肠外给药碳青霉烯类药物ME1036（CP5609）对耐甲氧西林葡萄球菌的体外活性
Antimicrob Agents Chemother. 2004 Aug;48(8):2831-7. doi: 10.1128/AAC.48.8.2831-2837.2004.
4
In vitro activity of oral cephalosporin BAY v 3522 compared with other oral cephalosporins.
Drugs Exp Clin Res. 1990;16(10):515-25.
5
In vitro antibacterial activity and pharmacodynamics of new quinolones.新型喹诺酮类药物的体外抗菌活性及药效学
Eur J Clin Microbiol Infect Dis. 2003 Apr;22(4):203-21. doi: 10.1007/s10096-003-0907-5. Epub 2003 Apr 1.
6
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.加替沙星、格帕沙星、左氧氟沙星、莫西沙星和曲伐沙星对4151株革兰氏阴性菌和革兰氏阳性菌的体外活性比较
Int J Antimicrob Agents. 2000 Feb;14(1):45-50. doi: 10.1016/s0924-8579(99)00143-0.
7
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.新型氟喹诺酮类药物ABT-492的体外抗菌效力及抗菌谱
Antimicrob Agents Chemother. 2003 Oct;47(10):3260-9. doi: 10.1128/AAC.47.10.3260-3269.2003.
8
In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.新型氟喹诺酮类药物DK-507k的体外和体内抗菌活性
Antimicrob Agents Chemother. 2003 Dec;47(12):3750-9. doi: 10.1128/AAC.47.12.3750-3759.2003.
9
In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.曲伐沙星及其他五种氟喹诺酮类药物的体外抗菌活性
Chemotherapy. 1998 Mar-Apr;44(2):85-93. doi: 10.1159/000007097.
10
In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.新型氟喹诺酮类药物E-3846对革兰氏阴性菌和革兰氏阳性菌的体外活性
Chemioterapia. 1987 Jun;6(2 Suppl):149-51.
引用本文的文献
1
Updated Review on Clinically-Relevant Properties of Delafloxacin.关于德拉氟沙星临床相关特性的最新综述
Antibiotics (Basel). 2023 Jul 28;12(8):1241. doi: 10.3390/antibiotics12081241.
2
The activity of delafloxacin and comparator agents against bacterial pathogens isolated from patients with cancer.达氟沙星及对照药物对从癌症患者中分离出的细菌病原体的活性。
JAC Antimicrob Resist. 2023 Mar 27;5(2):dlad034. doi: 10.1093/jacamr/dlad034. eCollection 2023 Apr.
3
Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline.德拉氟沙星、非那沙星和扎博沙星：抗生素研发中的新型氟喹诺酮类药物。
Antibiotics (Basel). 2021 Dec 8;10(12):1506. doi: 10.3390/antibiotics10121506.
4
Drugs for Gram-Negative Bugs From 2010-2019: A Decade in Review.2010 - 2019年用于革兰氏阴性菌的药物：十年回顾
Open Forum Infect Dis. 2020 Jul 3;7(7):ofaa276. doi: 10.1093/ofid/ofaa276. eCollection 2020 Jul.
5
Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.德拉沙星：治疗急性细菌性皮肤和皮肤结构感染的综述。
Drugs. 2020 Aug;80(12):1247-1258. doi: 10.1007/s40265-020-01358-0.
6
Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms.用于多重耐药革兰氏阳性微生物的新型抗生素
Microorganisms. 2019 Aug 18;7(8):270. doi: 10.3390/microorganisms7080270.
7
Profile of a Novel Anionic Fluoroquinolone-Delafloxacin.一种新型的阴离子氟喹诺酮类药物——德拉沙星的特性。
Clin Infect Dis. 2019 Apr 8;68(Suppl 3):S213-S222. doi: 10.1093/cid/ciy1079.
8
9
Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin.达氟沙星的临床药代动力学与药效学
Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):305-317. doi: 10.1007/s13318-018-0520-8.
10
Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin.急性细菌性皮肤和皮肤结构感染的新兴治疗选择：聚焦于静脉注射达氟沙星。
Infect Drug Resist. 2018 Apr 4;11:479-488. doi: 10.2147/IDR.S142140. eCollection 2018.
本文引用的文献
1
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.新型氟喹诺酮类药物ABT-492的体外抗菌效力及抗菌谱
Antimicrob Agents Chemother. 2003 Oct;47(10):3260-9. doi: 10.1128/AAC.47.10.3260-3269.2003.
2
Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program.流感嗜血杆菌和卡他莫拉菌对口服抗菌药物的敏感性趋势：哨兵抗菌监测计划的五年报告
Diagn Microbiol Infect Dis. 2003 Sep;47(1):373-6. doi: 10.1016/s0732-8893(03)00089-0.
3
Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000).1998 - 2000年美国耐氟喹诺酮类肺炎链球菌临床分离株的交叉耐药性、亲缘关系及等位基因分析
J Antimicrob Chemother. 2003 Aug;52(2):168-75. doi: 10.1093/jac/dkg309. Epub 2003 Jul 1.
4
Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000).北美住院患者肺炎相关病原体的发生情况及药敏模式：哨兵抗菌监测研究（2000年）结果
Diagn Microbiol Infect Dis. 2003 Apr;45(4):279-85. doi: 10.1016/s0732-8893(02)00540-0.
5
Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study.1999 - 2000年北美社区获得性呼吸道病原体的抗菌药物敏感性：PROTEKT监测研究结果
Diagn Microbiol Infect Dis. 2003 Apr;45(4):251-9. doi: 10.1016/s0732-8893(02)00522-9.
6
In vitro antibacterial activity and pharmacodynamics of new quinolones.新型喹诺酮类药物的体外抗菌活性及药效学
Eur J Clin Microbiol Infect Dis. 2003 Apr;22(4):203-21. doi: 10.1007/s10096-003-0907-5. Epub 2003 Apr 1.
7
Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).美国肺炎链球菌中抗菌药物耐药相对率的相关因素：TRUST监测项目（1998 - 2002年）的结果
Clin Infect Dis. 2003 Apr 15;36(8):963-70. doi: 10.1086/374052. Epub 2003 Apr 2.
8
Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).加替沙星（BMS284756）对皮肤和软组织感染相关病原体活性的地理差异：SENTRY抗菌监测项目（2000年）报告
Diagn Microbiol Infect Dis. 2002 Aug;43(4):303-9. doi: 10.1016/s0732-8893(02)00415-7.
9
Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus.社区获得性耐甲氧西林金黄色葡萄球菌的抗菌药敏性及分子特征分析
Diagn Microbiol Infect Dis. 2002 Jul;43(3):225-32. doi: 10.1016/s0732-8893(02)00394-2.
10
Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.自1994 - 1995年以来美国肺炎链球菌对氟喹诺酮类药物的耐药性
Antimicrob Agents Chemother. 2002 Mar;46(3):680-8. doi: 10.1128/AAC.46.3.680-688.2002.
Zotero 插件